https://s21.q4cdn.com/317678438/files/doc_downloads/Transcri...
“ what we believe, what I believe is as we move from a pandemic state, from a pandemic situation to an endemic situation, normal market forces, normal market conditions will start to kick in. And factors like efficacy, booster ability, clinical utility will basically become very important, and we view that as, quite frankly, a significant opportunity for our vaccine from a demand perspective, from a pricing perspective, given the clinical profile of our vaccine. So clearly, more to come here. But we think as this shifts from pandemic to endemic, we think there's an opportunity here for us.”
* If their reaction to the first dose was life-threatening due to anaphylaxis etc.
* If their reaction to the first dose was scary and/or long and they’re too scared to get the second dose.
* If they heard the first dose was highly effective on its own and don’t understand the risk around the long term efficacy.
* If they already had COVID (or just thought they did) and were treating the vaccine as a booster.
* If they had the first dose but their second dose was interdicted by misinformation.
* If they died or became incapacitated before getting their second dose.
* They did get a second dose but there are problems with the data collection.
* They had problems scheduling the second dose or couldn’t afford the risk of time off from work.
* They’re neglectful of their health.
Still, I wonder where we're going with the number of injections to be done. How many will we need in 2 to 3 years? 5 or 6? And what about people who are late on their jabs? This is gonna be some real mess. I guess the only way out is finding a functional cure for COVID.
